Low-dose computed tomography screening for lung cancer in Tianjin: a preliminary clinical analysis of baseline screening and follow-up results
10.3969/j.issn.1000-8179.2017.20.474
- VernacularTitle:天津地区低剂量CT肺癌基线筛查与随访的初步临床分析
- Author:
GAO ZHONGSONG
1
;
YE ZHAOXIANG
;
ZHANG PENG
;
CUI XIAONAN
;
XIE YONGSHENG
;
HAN LIZHU
Author Information
1. 天津医科大学肿瘤医院放射科
- Keywords:
lung cancer screening;
low-dose CT;
baseline;
follow-up;
computer-aided detection
- From:
Chinese Journal of Clinical Oncology
2017;44(20):1034-1039
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of low-dose computed tomography (LDCT) baseline and follow-up scans of lung cancer screening and to analyze lung nodules and other thoracic lesions detected from baseline and follow-up. Methods:A total of 650 sub-jects were enrolled in the LDCT lung cancer screening program, and investigators mainly focused on the analysis of 548 subjects who participated in the follow-up scan. The investigators recorded the nodules and other lesions of baseline screening, compared them with the follow-up images, and recorded their progress. Results:A total of 101 subjects were positive in the baseline screening, with a positivity rate of 18.4%. Six cases of lung cancer were confirmed by pathology, with a detection rate of 0.92%(6/650). The detection rate of lung cancer in female non-smokers (1.59%) was higher than that in male smokers (1.04%) without significant difference (P=0.624). Detected in the follow-up scan were 19 cases of new nodule-positive subjects. The positive rate for new nodules was 3.5%(19/548). The difference between the three-and two-dimensional levels was statistically significant. Conclusion:The effect of LDCT screen-ing for early lung cancer is significant. The detection rate in female non-smokers was not significantly higher than that in male smok-ers. Thus, LDCT lung cancer screening is equally significant for both sexes. The computer-aided detection (CAD) volume measurement technique is better to evaluate the progress of nodules during the follow-up interval.
